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Abstract
Promising therapies for cartilage repair are translated through large animal models toward human 
application. To guide this work, regulatory agencies publish recommendations (“guidance 
documents”) to direct pivotal large animal studies. These are meant to aid in study design, outline 
metrics for judging efficacy, and facilitate comparisons between studies. To determine the 
penetrance of these documents in the field, we synthesized the recommendations of the American 
Society for Testing and Materials, U.S. Food and Drug Administration, and European Medicines 
Agency into a scoring system and performed a systematic review of the past 20 years of preclinical 
cartilage repair studies. Our hypothesis was that the guidance documents would have a significant 
impact on how large animal cartilage repair studies were performed. A total of 114 publications 
meeting our inclusion criteria were reviewed for adherence to 24 categories extracted from the 
guidance documents, including 11 related to study design and description and 13 related to study 
outcomes. Overall, a weak positive trend was observed over time (P=0.004, R2=0.07, 
slope=0.63%/year), with overall adherence (the sum of study descriptors and outcomes) ranging 
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from 32±16% to 58±14% in any individual year. There was no impact of the publication of the 
guidance documents on adherence (P =0.264 to 0.50). Given that improved adherence would 
expedite translation, we discuss the reasons for poor adherence and outline approaches to increase 
and promote their more widespread adoption.
INTRODUCTION
Articular cartilage defects are common (1–4) and, left untreated, can lead to disabling joint 
disease (5). As such, there has been considerable focus on developing new treatments. The 
field of regenerative cartilage therapeutics has evolved substantially since the advent of bone 
marrow stimulation and abrasion arthroplasty techniques (6, 7), to include both autograft and 
allograft osteochondral transplantation (8, 9) and the widespread use of cell-based 
autologous chondrocyte transplantation (ACI) (10). Likewise, regenerative medicine–based 
approaches have been developed to improve on these techniques [for review, see (11)], 
including in vitro–grown engineered constructs (12–14), biomaterial-based cell delivery 
systems (for next generation ACI), and materials that serve as adjuvants to repair (used in 
conjunction with microfracture), with several “first in human” clinical trials of new repair 
technologies reported over the last few years (15–17). The appearance of these reports 
speaks to the intense innovation occurring within this domain to provide both functional and 
durable repair of cartilage injuries.
In most (if not all) cases, translation of emerging regenerative approaches to clinical practice 
involves preclinical evaluation in an animal model. Large animal models (in particular 
equine, ovine, caprine, porcine, and canine) are commonly used for final (pivotal) preclinical 
studies. Critical evaluation of new technologies in large animals can highlight the safety and 
efficacy of new therapies, and also redirect designs to improve efficacy when preliminary 
versions fail. A number of recent reviews outline the strengths and weaknesses of these 
various large animal repair models (18–21).
Beyond selecting a species in which to perform the pivotal trial, investigators must carry out 
a well-performed study that will be accepted by their peer community and the regulatory 
agencies that will consider data generated toward the initiation of a human clinical trial. To 
that end, several resources exist to orient investigators to best practices, including guidance 
documents published by governing agencies including the U.S. Food and Drug 
Administration (FDA, first draft 2007) (22) and the European Medicines Agency (EMA, 
first draft 2008) (23) as well as expert-panel reports by the American Society for Testing and 
Materials (ASTM International, first draft 2005) (24) and the International Cartilage Repair 
Society (ICRS) (20). These guidance documents provide specific details related to study 
design, desired time points, and endpoint analyses to guide the proper execution of the study 
(Table S1 and Table S2). In each document, however, there is room for interpretation, 
acknowledging ongoing developments in the field and the difficult decisions that are made in 
carrying out such studies. For example, the language on an appropriate defect location is 
vague, recommending that investigators choose an “orthotopic” (23) or “similar to human” 
(22) site (see Table S1). Furthermore, these documents provide guidance but are not per se 
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mandates, and so investigators can make their own decisions as to the appropriate study 
design and the type and number of outcome assays employed.
Given the maturation of the field of cartilage repair as well as the recent publication of these 
guidance documents, we were curious as to the extent to which the field had incorporated 
these recommendations into their work. To answer this question, we performed a systematic 
review inclusive of the most common large animal models, capturing data from full-length 
peer-reviewed publications over the last two decades (1994–2014, see Supplementary 
publication listing). We then reviewed the extant literature that met our inclusion criteria 
(studies reporting on repair of chondral defects in large animal species) and used quantitative 
analysis to determine the degree to which these studies adhered to the guidance document 
recommendations.
Our overall hypothesis was that the field as a whole would show a quantifiable improvement 
in adherence to the guidance documents over the time period considered. Given that these 
documents appeared during the period of our review (for example, 2005, 2007, and 2008 for 
ASTM, FDA, and EMA, respectively), we postulated that there would be an inflection in the 
trajectory of adherence, with greater adherence after the publication of the guidance 
documents. We further expected that those studies with longer-term time points and those 
using larger species (both of which would increase study costs) would show a greater 
adherence to these published criteria, as these would more likely represent pivotal rather 
than preliminary studies.
RESULTS
The initial review of the extant guidance documents defined categories for subsequent 
analysis. These are defined in Table S1 for study descriptors and Table S2 for study 
outcomes, according to the governing agency defining the standard. Those agencies that 
focus on standardization of measures (for example, ASTM) provide the greatest detail in 
terms of execution of outcome assays, whereas other publications (for example, EMA) were 
intended as guidelines and so provide less-specific details (Fig. 1).
Next, we used our established inclusion/exclusion criteria to identify peer-reviewed studies 
for consideration. Our search identified 1187 articles on cartilage repair in large animals 
published as full-length manuscripts over the last 20 years (see Materials and Methods). 
Application of exclusion criteria reduced the total number to 123 for analysis. Of these, 9 
were not eligible upon detailed review. Thus, 114 studies were included in this analysis, of 
which 20 were conducted in horses, 23 in sheep, 18 in goats, 41 in (mini) pigs, and 12 in 
dogs (Fig. 2).
All studies were reviewed and scored by one of the three reviewers. When questions arose, 
each of the three graders reviewed and discussed the publication, and a consensus score was 
assigned. Scores for all studies considered (columns) and their degree of adherence to each 
of the 24 categories (rows) was visualized by color-mapping the resulting scores for each 
study (Fig. 3). These were further analyzed by calculating the percentage of studies 
reporting on each study descriptor and study outcome.
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The number of published large animal cartilage repair studies ranged from 1 per year to a 
peak of 16 in 2009 (Fig. 4A). Overall adherence to guidance documents (that is, overall 
assessment) showed a weak positive trend with time (P=0.004, R2=0.07, slope=0.63%/year, 
Fig. 4B), ranging from 32±16% to 58±14% for a single year. However, there was no effect 
of the publication of the guidance documents on adherence (documents published in 2005, 
2007, and 2008). That is, the effect of time on the level of adherence did not change in the 
period following any one of these publications (P=0.26 to 0.50). In fact, the slope of 
adherence versus time decreased after issuance of the guidance documents (0.89 to 1.11%/
year before publication versus 0.07 to 0.48 after publication). Since 2003, most published 
studies had an overall adherence of ~50%.
We also considered adherence in each subset of categories, study descriptors (11 categories) 
and study outcomes (13 categories). Not surprisingly, this analysis showed that adherence to 
study descriptors was, without exception, higher than adherence to study outcomes (Fig. 
4C). The only category not well covered in the subset of study descriptors was relative lesion 
size (<5% of all studies). This is an important category on which to report given that 
relatively small lesions may occupy a significant portion of the joint in some species (25). 
Of the 13 study outcomes, histological analysis was most commonly reported, with 97% of 
studies reporting on this category. It should be noted, however, that there was little 
consensus on the histological methodology employed, with some studies simply reporting 
very basic histology and others performing multiple stains and visualization by advanced 
imaging modalities (for example, polarized light). Likewise, some studies provided semi-
quantitative scoring of histological outcomes, whereas others did not, and those that did 
provide semi-quantitation used a number of different scoring systems. Of the remaining 
study outcomes, only gross view (80%) and defect fill (60%) were reported by >50% of the 
studies examined. As with histology, a variety of qualitative and semi-quantitative 
assessments were employed. All other study outcomes fell below 50% adherence, with 
follow-up arthroscopy (reported by <8%) and gene expression (reported by 11%) being the 
two least reported.
When these metrics were analyzed across species, a similar pattern was observed (Fig. 4D). 
In general, findings showed that for overall adherence, equine > canine > ovine = caprine > 
porcine. For all species, study descriptors showed a higher level of adherence than the study 
outcomes. Somewhat in keeping with one of our initial hypotheses, studies that used horses 
showed a slightly higher score in terms of overall adherence (59±12%) and study outcomes 
(50±20%) compared to other species. These differences were only significant in comparison 
to (mini-)pigs, however, where overall adherence was 49±10% (P<0.001 versus equine) and 
study outcome adherence was 30±12% (P<0.01 versus equine). No other differences were 
observed among species.
Another of our original hypotheses was that studies that were longer or larger would have 
better adherence. Contrary to this hypothesis, the correlation between duration and overall 
adherence was 0.27 (with a P value of 0.003), indicating a weak correlation (Fig. 4E). 
Likewise, the correlation relating the number of animals used in a study to overall adherence 
was 0.001 (P = 0.994), suggesting no correlation existed between these factors (Fig. 4F). 
Given the labor and cost involved in studies using a large number of animals for a long 
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duration, it was surprising to find such weak correlations. Additional data comparing 
numbers of animals used, unilateral versus bilateral surgeries, numbers of groups per study, 
samples per group, and defects per joint across species are presented in the Supplementary 
Materials.
DISCUSSION
Activity in the field of cartilage repair and regeneration is well evidenced by the increase in 
number of translational cartilage repair studies over the last two decades (Fig. 4A) as well as 
several recent “first-in-human” reports. Guidance documents published by U.S. and 
European regulatory agencies provide direction for performing animal studies (20, 22–24), a 
framework in which to validate safety and efficacy prior to human trials, and should enable 
better comparison between studies to expedite progress in the field. Given that the first of 
these guidance documents was published ~2005, our overriding hypothesis was that the field 
as a whole would show a quantifiable improvement in reporting on the study design and 
outcome criteria outlined in these documents. To assess this, we performed a formal 
systematic review and also extracted quantifiable adherence data from the past two decades 
of large animal research in terms of study descriptors and study outcomes. In doing so, we 
tested the hypothesis that there would be an inflection in the trajectory of adherence to these 
guidance documents based on the timing of their publication. On the basis of our experience 
with such model systems, we further expected to find that those studies with longer-term 
time points and those that used larger species and a greater number of animals (both of 
which would increase study costs) would show a greater adherence to these published 
criteria.
Unfortunately, our initial hypotheses were generally not supported by the data extracted 
from the literature. Although there has been a slow increase in overall adherence to the 
guidance criteria over the past two decades (with recent studies reaching 50 to 60%), there 
was little impact (that is, change in trajectory) as a consequence of the publication of the 
guidance documents. Even more surprising, there seemed to be only weak or nonexistent 
correlations between overall adherence and the length of the study or cost of the study 
animals used. On the basis of the publications analyzed and the methodology used in this 
study, it is clear that the field has not responded to the publication of the guidance 
documents, and so there is little homogeneity in the reporting of these studies and the 
outcome assays that are being employed.
To probe the data set a bit further, we subdivided the analysis into study descriptors and 
study outcomes, in which the former enumerated basic information regarding the animals 
and surgical procedures and the latter summed the number of outcome assays used with 
respect to those suggested by the guidance documents. This analysis showed that the study 
descriptor categories were in general met at a rate of ~75%. It was surprising that the rate of 
adherence was not higher, and suggested to us that there is simply a lack of standardization 
in the field in terms of reporting on these parameters. Improvement in adherence in these 
categories could be achieved if authors simply reported on the age, weight, and gender of the 
animals used; these last two parameters were reported by <50% of the studies analyzed but 
can have a major influence on cartilage repair potential (in humans) (26–28). In addition, in 
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a complicated study design, the overall study is best understood when visualized in a flow 
chart, as is commonly used in clinical studies (29). The above are standard components of 
any animal protocol, but are not generally included in the extant literature. One 
recommendation for the field might be to better adhere to the ARRIVE (Animals in 
research: Reporting in vivo experiments) guidelines for publication (30), with select 
components of approved animal protocols (such as flow diagrams, tables of weights, gender, 
groups for analysis) provided with each published animal study (as supplementary material), 
so that the full complement of information is easily accessible to the community while not 
making published methods burdensomely long.
Some descriptors that directly influence experimental outcomes were reported on but done 
so with insufficient detail so as to enable replication. For instance, most studies reported 
some aspect of post-surgical rehabilitation, but few provided detailed descriptions (with the 
exception of those studies performed in horses), despite this having a profound impact on 
outcomes in both humans and animals (31). In addition, the description of the lesion depth 
and type was often vague or missing and did not always specifically differentiate between 
partial chondral, full chondral, and osteochondral defects [as described by Cucchiarini et al. 
(32)]. If the technique and visualization allows, the description of the defect creation should 
also carefully describe whether the calcified cartilage was removed or not, and if bleeding 
into the defect was present–again, these are rarely noted in published studies despite their 
impact on regeneration.
When it came to study outcomes, adherence to the guidance documents was by far less 
robust, with most studies falling in the range of ~40% adherence. Indeed, only three 
categories (histology, gross visualization, and assessment of defect fill) were reported on by 
more than 50% of the studies we analyzed. Many other important categories (for example, 
biomechanics and biochemistry of the regenerate tissue) were reported on by fewer than 
25% of these studies. In some categories, such as relative defect size and gene expression, 
only one of the documents recommended reporting on this parameter, and so low adherence 
here might reflect an overall lack of consensus as to the value of such outcomes. 
Alternatively, some assays, such as follow up arthroscopy, are not possible in all species, and 
so poor adherence in this category might reflect the technical challenges inherent to some 
species. Even with these caveats, however, our findings suggest that there is very little 
consensus in the field as to the most important study outcomes to measure and report in 
these large animal models.
DO AS THEY SAY, NOT AS WE DO
Although it seems logical to follow the guidelines set forth by regulatory agencies (“do as 
they say”), researchers appear to largely ignore these recommendations (“not as we do”). In 
fact, the gulf between what they say we should do and what we actually do is quite large. 
Subjecting our own recent large animal model of cartilage repair (33) to this same analysis 
shows that our study fares no better than the industry standard. For our recent cartilage 
repair study in minipigs, we achieved an overall adherence of only 56%; whereas our 
adherence to study descriptors was a respectable 73%, our adherence to study outcomes was 
a lowly 42%. Given that adherence to study descriptors are generally at an acceptable level 
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and because improvements in this area could be easily made, we will focus our 
recommendations on study outcomes, in which a change in approach will be required for 
significant improvements to be made across the field.
There are several potential reasons for a lack of adherence in terms of study outcomes. First 
and foremost, not every study group has access to the infrastructure and expertise needed to 
conduct certain measurements. Indeed, those outcomes that are relatively easy and 
inexpensive to perform (histology and gross view imaging) are well covered across studies, 
whereas those requiring specialized expertise (for example, mechanical testing) and 
equipment (for example, follow-up MRI) are underrepresented. A solution to this 
infrastructure and expertise problem might be build better collaborations and research 
networks, or to create designated federally funded core facilities for the performance of 
these more advanced assays.
A second (and simple) reason for the low adherence rate might be that not every study has 
the same intent (for example, some being considered to be “pilot” and others “pivotal”). In 
pilot studies [including our own (33)], one naturally focuses on only one or a few outcomes 
within the expertise of the particular group and most predictive (in the opinion of the group) 
for what the experimental groups intend to pursue for further study. Such pilot studies are 
critical steps in advancing any technology and certainly need to be performed. However, it is 
still crucial to extract as much useful information as possible by increasing the number of 
outcome measurements obtained from each specimen in a non-destructive manner. Further, 
development and use of tools for repeated measures (for example, MRI, arthroscopy) on the 
same animals might improve the depth of reported outcomes while not overly increasing 
costs.
Another consideration is that different cohorts (basic scientists, engineers, clinicians) likely 
have differing opinions as to which of the outcomes is most important. The guidance 
documents are under constant review and improvement, and new insights from the field are 
continually incorporated (34). Given that so many outcome measures are simply not reported 
at present, it might well be that these documents should be refined further to develop a 
minimal set of recommended outcome measurements that is agreed upon (and followed) by 
all stakeholders.
A final, and perhaps the most important, factor defining the overall level of adherence is of 
course the amount and source of funding. Large animal trials are expensive, and not every 
group has the resources to analyze the full set of recommended outcomes, even though the 
marginal costs for performing additional assays might be small compared to the animal 
study cost. In some cases, funding might be available only for a pilot trial, whereas in other 
cases, funding might be available for a pivotal study with the intent of translating the 
findings to humans. This is not to say that pilot trials shouldn’t be done. Rather, these studies 
should be performed and defined, perhaps with a different set of criteria for moving 
technology to the next and more rigorous (pivotal) level. An additional complication is that 
when studies are industry-sponsored, there is the added element of financial pressure, and 
not every industry-sponsored study is intended for open publication in the literature (limiting 
our ability to capture these data). Here, the need to commercialize a product as soon as 
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possible might set objectives at the level of providing just enough evidence to regulatory 
bodies (but not to the general public) so as to meet the bar for market admittance and 
initiation of a human clinical phase I trial. This is in no way judgment, but rather speaks to 
the reality of the world we live in, wherein timing, competitive advantage, and economy 
might mean the difference between market success and bankruptcy.
To address these deficiencies, our summary recommendation for those performing large 
animal studies is to “do as they say, not as we do”. The guidance documents are quite robust, 
and all suggested outcomes have value and will accelerate progress if more routinely 
employed. The community should convene and come to consensus on definitions of minimal 
requirements that identify pilot and pivotal studies, and both editorial and regulatory bodies 
should enforce these criteria in advancing publications or new products. To make this 
possible and increase adherence overall, regulatory and funding agencies should provide 
additional resources to enable this more rigorous transition to translation. Coordinated effort 
and funding are necessary to improve outcomes and expedite the development of new 




For this systematic review, guidelines from three agencies were first synthesized to develop 
categories by which to assess the literature. Next, the literature on animal models to study 
cartilage repair were systematically reviewed and scored based on the adherence to these 
categories (search methodology and inclusion/exclusion criteria are described below). Data 
generated were then analyzed statistically to assess the impact of the publication of the 
guidance documents on whether these categories were reported on by the identified studies, 
as well as to assess species-specific differences in methods and reporting standards.
Synthesis of recommendations and categories for assessment
Three guidelines were considered: 1) the US Food and Drug Administration (FDA) 
Guidance for Industry: Preparation of IDEs and INDs for Products Intended to Repair or 
Replace Knee Cartilage (last accessed 4/30/2014) (22), 2) the European Medicines Agency 
(EMA) Guideline on Human Cell-based Medicinal Products (23) with International 
Standard ISO/EN 10993 (35) (last accessed 4/30/2014) and 3) the American Society for 
Testing and Materials (ASTM) International F2451-05 (2010) Standard Guide for in vivo 
Assessment of Implantable Devices Intended to Repair Articular Cartilage (24). 
Recommendations from these documents (Table S1 and Table S2) were sorted as ‘study 
descriptors’ (Table S1) and ‘study outcomes’ (Table S2). A total of a 24 categories were 
identified (11 study descriptors and 13 study outcomes).
Literature search and scoring
The literature search, screening, and eligibility testing followed the Preferred Reporting 
Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines (29). To retrieve 
published studies employing the five most common large animal models (horse, sheep, goat, 
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(mini-) pig, and dog) we searched the PubMed database (www.ncbi.nlm.nih.gov/pubmed) 
and the official journal of the International Cartilage Repair Society (ICRS) “Cartilage” on 
April 18th 2014, using the search term “cartilage_ specific species name_repair” (see Fig. 2). 
The two primary inclusion criteria included that the study be in a large animal (dog, pig, 
goat, sheep, horse), that the defect be chondral only (that is, not including the subchondral 
bone). The former represented studies that were testing a mature technology in valid pre-
clincial model, and the latter was enforced to focus (and restrict) our analysis to cartilage 
repair apporaches (rather than appoaches seeking to repair both cartilage and bone at the 
same time). After screening articles for inclusion and exclusion criteria and eligibility, a total 
of 114 studies were identified and reviewed for adherence. If a category was fully reported, 
the study was credited one point. If the category was not reported/measured, a score of zero 
was assigned. If a category was partially reported, a score of 0.5 was assigned. Eligibility 
and scoring were reconciled by group discussion when not clear (i.e., all authors read the 
manuscript in question and weighed in to assign the score). Points per study were calculated 
as percentages of “overall adherence” (all 24 categories included), “study descriptors” (11 
categories), or “study outcomes” (13 categories).
Statistical analysis
Statistical analysis was performed using SPSS® (Version 20, IBM, NY, USA). Pearson’s 
correlation coefficients were computed for study duration versus overall adherence 
(α=0.05). ANOVA with Bonferroni post-hoc testing (α=0.05, two-tailed) was used to make 
comparisons for species specific statistics after establishing normality of data (Kolmogorov-
Smirnov test). To assess whether individual guidance documents impacted adherence, 
ANCOVAS were performed, with a separate analysis for each document (i.e., using years 
2005, 2007, or 2008 as the grouping variable) using time as a co-variate (α=0.05, two-
tailed). The interaction term between group and time was used to indicate if a particular 
document significantly impacted adherence.
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Recommendations from regulatory agencies for appropriate descriptors and outcomes for 
translational large animal studies in cartilage repair. Color scheme indicates whether the 
documents provide detailed (=green), loose (=yellow), or no (=red) recommendations in a 
category.
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Literature search, screening, and eligibility testing using the Preferred Reporting Items for 
Systematic Reviews and Meta-analyses (PRISMA) guidelines (29).
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Array depiction and quantification of adherence to guidance document recommendations. 
Each row indicates a different category (descriptors on top, outcomes on bottom), while each 
column represents an individual study. Green indicates full adherence, red indicates non-
adherence, and yellow indicates partial adherence. Bars at right show average percentage 
adherence across all studies in a given category.
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(A) Number of studies per year (*through 4/18/14). (B) Overall adherence by study and 
year. Vertical lines indicate the time of publication of the *ASTM, # FDA, and § EMA 
documents. Regression shows slight increase in overall adherence with time (p=0.004, 
R2=0.07, slope=0.63%/year). C) Mean adherence per year, broken out into overall, study 
descriptors, and study outcomes. Study descriptors were reported at a higher level than study 
outcomes. Standard deviation is shown for overall adherence only. D) Adherence (in 
percent) across species (white bars = study descriptors, hatched bars = study outcomes, 
black bars = overall adherence, *P<0.05). E) Correlation between overall adherence and 
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study duration (R2=0.075, P =0.003) and F) overall adherence and the number of animals 
(R2<0.001, P =0.994).
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